Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol. The ...

Daiichi Sankyo was however unable to secure approval for that indication in both the US and Europe, setting back its plans for the drug.

Daiichi Sankyo is dedicated to bringing innovative therapies to as many patients as possible, and as quickly as possible. Its approach builds on more than 40 years of experience in oncology and a ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

IGI Therapeutics SA, has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in ...

Reuters.com is your online source for the latest Europe news stories and current events, ensuring our readers up to date with any breaking news developments ...

Daiichi Sankyo Co. Ltd. ADR Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as ...